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species which was named Clostridium neonataie. The 
point-prevalence survey also revealed that 5 of 24 
neonates had C neonatale in their stool. Clonality of 
the C neonatale isolates from the outbreak and the 
point-prevalence survey were confirmed by PFGE. All 
showed identical banding patterns. The organism has 
been deposited with the ATCC (#BAA-265) and with the 
CCUG (#46077). The C neonatale is a strong fermenter 
of lactose with lactic acid as a major end product and 
moderate amounts of butyric and acetic acids. It digests 
milk with gas and butyric acid production which fit recent 
suggestions that these characteristics are necessary for an 
organism to stimulate the development of NEC. Five of 
the six neonates were 235 weeks gestation which may 
explain the low mortality rate (1 of 6). 
Conclusions: We describe an outbreak of NEC 
associated with a novel species, C.neonatale; we suggest 
that in larger neonates, carriage of this Clostridium 
species may be a necessary first step in the multistage 
pathogenesis of NEC. 
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Objective: It has been shown that IgG given intra- 
venously (IVIG) as well as plasma derived IgA 
delivered orally offer protection to the very low birth 
weight infant (VLBW, < 15OOg) against necrotizing 
enterocolitis (NEC) and, in the case of IVIG, against late 
onset neonatal sepsis. It has been reported in the 
literature that mother’s milk offers similar protection. 
The objective of this study was to determine whether the 
levels of IgA in milk collected from human volunteers 
at different points post-partum varied over time, as this 
could have implications related to the use of pooled milk 
in these VLBW infants, if IgA levels are, in fact, 
correlated with this protection. 
Methods: All milk IgA levels were determined using 
nephelometry. Time points ranged from 10 days post- 
partum (pp) through 7.5 months pp. All samples were 
tested with controls consisting of: an IVIG preparation 
of known IgA content, IgA negative serum, normal 
serum and PBS as a negative control. 
Results: There was IgA detectable in all samples from 
day 10 pp onward. (There were no available samples for 
days l-10). Levels of IgA were substantial at all time 
points, and did not drop off significantly through at least 
7.5 months pp. Specific IgA antibodies directed against 
tetanus toxin, PNPS, Haemophilus influenzae type B, and 
rotavirus were seen at all time points tested. 
Conclusions: IgA directed against specific pathogens 
is present in sizable amounts in breast milk over a 
prolonged period. It may be one of the components of 
breast milk responsible for the protection afforded 
VLBW neonates against NEC and sepsis. As it is present 
in significant levels for prolonged periods, pooled milk 
given to these infants may have the same beneficial 
effects previously documented for mother’s own milk, 
regardless of when, the milk was obtained post-partum. 
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Background: Primary immunodeficiency in children 
results in impaired immune responses to a number of 
vaccine-preventable infections. Secondary immuno- 
deficiencies are associated with many illnesses (eg human 
immunodeficiency virus (HIV) disease) and treatments 
(eg chemotherapy, haemopoietic stem cell transplants 
[HSCT], solid organ transplants [SOT]). The nature and 
kinetics of immune reconstitution post-HSCT, and the 
potentially lethal infectious complications of immuno- 
suppressive treatment, eg in SOT recipients, are well 
documented. Although opportunistic organisms are 
considered to pose the most serious infective threat to 
immunocompromised children, common bacterial and 
viral infections against which immunisations are 
available may also cause substantial morbidity or even 
death (eg pneumococcal infection late after HSCT or 
SOT). Many studies have documented significant 
reductions in specific antibody concentrations after 
HSCT, and restoration of protective titres in most 
children after reimmunisation. However, there is little 
published data about immunisation in other groups of 
immunocompromised children. Nevertheless, most such 
children are likely to benefit from continuation or 
commencement of active immunisation, provided 
certain live vaccines are avoided when appropriate. 
Unfortunately, proof of benefit in terms of reduced 
morbidity and mortality is not yet available. Despite 
broad recommendations concerning immunisations in 
these children, clinical practice varies considerably, 
particularly concerning the content and timing of 
immunisation schedules. 
A Working Party of the Royal College of Paediatrics 
and Child Health was asked to develop guidelines for 
the immunisation of immunocompromised children. 
Methods: Information was collated from formal com- 
puterised searches and personal knowledge of the 
literature, expert committee reports, and the clinical 
experience and practice of respected authorities. The 
paucity of controlled trials prevented development of 
evidence-based guidelines. Instead a “Best Practice 
Statement” (BPS) was written. 
Results: The BPS includes detailed recommendations 
for immunisation in children: (1) primary immuno- 
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deficiency, (2) after standard chemotherapy, (3) post- 
HSCT, (4) post-SOT, (5) inflammatory diseases/im- 
munosuppressive treatment, (6) HIV infection, (7) other 
groups. The recommendations will be outlined and are 
available on the RCPCH website. 
Conclusion: The introduction of the BPS should allow 
a consistent approach to immunisation of immuno- 
compromised children, and if this is confirmed at audit, 
will stimulate further research necessary to generate the 
solid evidence base that is required to support future 
recommendations. 
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Patients and methods: 246 cases were investigated to 
assess risk factors and outcome of infections, appearing 
in 36 neonates with very low birth weight (VLBW) 
<15OOg to other 210 neonates, appearing in 2 years in 
tertiary referral neonatal centre. 
Results: The analysis of types of cultures: blood cultures/ 
catheter. tips, showed that, the rate of bacteraemia/sepsis 
in <15OOg birth weight newborn infants (41.67% vs. 7.62, 
PsO.0001) was more higher than in those of >15OOg 
birth weight; umbilical swaps were more significantly 
observed in VLBW newborn infants than (40% vs. 
19.44%, PsO.029) <15OOg birth weight. According to 
the analysis of etiology there were differences between 
two groups for Klebsiella/Enterobacter infection rate, 
which showed higher rate of infection in VLBW infants 
(69.44 vs. 40.95, P<O.O027). According to the localisation 
of infection: bacteraemia/sepsis were more frequently 
prevalent and more significantly related to <15OOg birth 
weight newborn infants (36.11% vs. 5.71%, P10.0001) 
than >15OOg birth weight. Conjunctivitis (P10.0445), 
omphalitis (P10.031) were more frequently observed 
in >15OOg birth weight newborn infants, vice versa. 
Antibiotics used in the treatment of neonatal infection 
in both groups with significant univariate analysis 
were: penicillins (PsO.0237) meropenem (PsO.OOOl), 
ceftazidin (P10.02), ceftriaxon (P<O.o002), gentamicin 
(P<O.O0016), and netilmicin (P<O.OOOl) which were 
significantly and frequently observed in VLBW neo-nates. 
In an univariate analysis of mother’s risk factors, cerclage 
was more frequently observed (P%O.O005) in VLBW. 
Conclusion: The clinical significance of outcome were 
clear, since cure rates were logically higher among 
>15OOg birth weight newborn infants (98.57 vs. 88.89, 
P10.0099) than <15OOg birth weight, in term of death 
on underlying disease (overall mortality) (P10.0029). 
However PVL (P<O.O2), and IVH (IIIJIV.) (P10.0099) 
were significantly related to <15OOg birth weight new- 
born infants. 
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Background: One of the side effects reported on p- 
lactam antibiotic use is clinically significant bleeding. 
Among the mechanisms proposed for this adverse 
reaction was thrombocytopenia and platelets dysfunction. 
As of 1999 we use piperacillin/tazobactam as part of 
the empiric treatment for persumed sepsis. Since, pre- 
term infants are more prone to develop intraventricular 
hemorhage(IVH), some concerns have been raised 
as for the use of p-lactam antibiotics in this high risk 
population. 
Objective: To study the appearance of possible side 
effects of P/T use in term and preterm infants, parti- 
culary the incidence of IVH. 
Methods: Data from medical records were retrospectively 
collected from infants treated with P/T. Cranial ultra- 
sound (CUS) findings before, during and after the use of 
P/T were compared. The following side effects of the 
treatment were examined: clinical symptoms (allergic 
rash, gastrointestinal (GIT) symptoms, change in urine 
output, change in blood pressure) and blood tests 
(complete blood count, liver enzimes, bilirubin and 
creatinine). 
Results: During 1999-2001 a total of 165 episodes of P/T 
treatment were studied. In 55 episodes the treatment last 
for 5-14 days. Mean birth weight was 1690t900gr and 
GA was 31.7k4.7. CUS finding included 4 infants with 
IVH. All discovered during first 3 days of live and before 
the introduction of P/T. Low platelets(PLT) count was 
noticed in 38% of the patients(but was not related to P/T 
treatment). There were no evidence of allergic reaction, 
significant decrease in blood pressure, GIT symptomes 
or a change in blood test results. 
In 110 episodes the treatment last for 2-4 days, BW 
1300+550,GA 29.9k3.8. IVH was noticed in 15 (13.6%) 
infants all ocured before introducing P/T and 37 (33.6%) 
infants had low PLT(unrelated to the use of P/T). None 
of the above side effects were described. 
Conclusions: There was no increase in the rate of IVH 
with the treatment of P/T even in preterm infants with 
low PLT count. No other side effects occurred in this 
group of patients. More studies are required regarding 
the use of P/T in the neonate. 
